These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 20530278

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors.
    Beck SD, Foster RS, Bihrle R, Donohue JP.
    Urology; 2007 Mar; 69(3):557-9. PubMed ID: 17382165
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors?
    Gerl A, Lamerz R, Clemm C, Mann K, Hartenstein R, Wilmanns W.
    Clin Cancer Res; 1996 Sep; 2(9):1565-70. PubMed ID: 9816334
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
    You B, Fronton L, Boyle H, Droz JP, Girard P, Tranchand B, Ribba B, Tod M, Chabaud S, Coquelin H, Fléchon A.
    Urology; 2010 Aug; 76(2):423-9.e2. PubMed ID: 20472276
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The value of tumor markers in testicular seminomas. Results of a prospective multicenter study.
    Weissbach L, Bussar-Maatz R, Mann K.
    Eur Urol; 1997 Aug; 32(1):16-22. PubMed ID: 9266226
    [Abstract] [Full Text] [Related]

  • 10. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
    Liu ZW, Zhou FJ, Han H, Qin ZK, Yu SL, Li YH, Ye YL, Teng XY.
    Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
    Stephenson AJ, Bosl GJ, Motzer RJ, Kattan MW, Stasi J, Bajorin DF, Sheinfeld J.
    J Clin Oncol; 2005 Apr 20; 23(12):2781-8. PubMed ID: 15837993
    [Abstract] [Full Text] [Related]

  • 18. Serum tumour markers in testicular and extragonadal germ cell malignancies.
    Klepp O.
    Scand J Clin Lab Invest Suppl; 1991 Apr 20; 206():28-41. PubMed ID: 1947758
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Nonseminomatous germ cell testicular tumors clinical stage I: differentiated therapeutic approach in comparison with therapeutic approach using surveillance strategy only.
    Ondrus D, Ondrusova M, Hornak M, Matoska J.
    Neoplasma; 2007 Apr 20; 54(5):437-42. PubMed ID: 17688374
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.